Skip to Main Content

Knowledge Center

Pandemics

Respiratory Outcomes and Lung Transplantation in COVID-19 Patients

What does COVID-19 do to the lungs? 

In approximately 5% of COVID-19 infections, respiratory and multi-organ failure occurs, and it is likely that many more individuals with a history of severe lung disease caused by the SARS-CoV-2 virus will require lung transplantation in the years to come. Still, lung transplantation in COVID-19 patients is an option of last resort.

RGA's Hilary Henly explores respiratory failure from COVID-19, long-term health outcomes after infection, and assessment criteria for lung transplantation. 

See also: Respiratory Outcomes and Lung Transplantation in COVID-19 Patients


As the pandemic evolves, new implications and data-driven insights will continue to emerge, which RGA will continue to investigate. Please contact us for insights.




The Presenter

  • Hilary Henly
    Global Medical Researcher
    RGA International Reinsurance Company dac
    Send email >

Summary

Curious about RGA's medical insights?  Contact us to learn more. 

This video was developed in conjunction with actuview, the first permanent international media platform for actuaries (www.actuview.com). actuview content reflects contributions from actuarial institutions, corporate partners and industry professionals. RGA is actuview’s sponsoring partner.

https://player.vimeo.com/video/713753218?h=39c4217644
  • COVID-19
  • Henly
  • Hilary Henly
  • lung disease
  • lung transplantation
  • morbidity improvement
  • organ failure
  • pandemic
  • respiratory failure
  • SARS-CoV-2
  • SARS-CoV-2 morbidity
  • SARS-CoV-2 mortality